Breaking the chronic cycle of inflammatory diseases.
Disease Focus
Chronic inflammatory diseases destroy lives every day. We are highly attuned to the serious comorbidities associated with chronic inflammatory diseases and to the limitations of treatments that provide only symptomatic relief.
Our focus is to pursue solutions that go beyond symptom control to halt disease progression and ultimately reduce mortality. That is the heart of the Evommune approach – addressing the underlying drivers of disease, not just its symptoms.
Our goal is to develop accessible innovations that not only address the symptoms of chronic inflammatory disease, but also halt disease progression and prevent medical complications in the future.
We are also targeting IL-18, a pro-inflammatory cytokine of the IL-1 family that regulates various immune processes that drive inflammation and is a potent modulator of ongoing inflammation. We are targeting IL-18 with a long-acting injectable therapeutic, EVO301, a SAFA-IL-18BP fusion-protein that is designed to neutralize the IL-18 inflammatory pathway.